Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2020

01-01-2020 | Breast Cancer | Preclinical study

Molecular determinants of drug response in TNBC cell lines

Authors: Nathan M. Merrill, Eric J. Lachacz, Nathalie M. Vandecan, Peter J. Ulintz, Liwei Bao, John P. Lloyd, Joel A. Yates, Aki Morikawa, Sofia D. Merajver, Matthew B. Soellner

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Login to get access

Abstract

Purpose

There is a need for biomarkers of drug efficacy for targeted therapies in triple-negative breast cancer (TNBC). As a step toward this, we identify multi-omic molecular determinants of anti-TNBC efficacy in cell lines for a panel of oncology drugs.

Methods

Using 23 TNBC cell lines, drug sensitivity scores (DSS3) were determined using a panel of investigational drugs and drugs approved for other indications. Molecular readouts were generated for each cell line using RNA sequencing, RNA targeted panels, DNA sequencing, and functional proteomics. DSS3 values were correlated with molecular readouts using a FDR-corrected significance cutoff of p* < 0.05 and yielded molecular determinant panels that predict anti-TNBC efficacy.

Results

Six molecular determinant panels were obtained from 12 drugs we prioritized based on their efficacy. Determinant panels were largely devoid of DNA mutations of the targeted pathway. Molecular determinants were obtained by correlating DSS3 with molecular readouts. We found that co-inhibiting molecular correlate pathways leads to robust synergy across many cell lines.

Conclusions

These findings demonstrate an integrated method to identify biomarkers of drug efficacy in TNBC where DNA predictions correlate poorly with drug response. Our work outlines a framework for the identification of novel molecular determinants and optimal companion drugs for combination therapy based on these correlates.
Appendix
Available only for authorised users
Literature
1.
Pareja F, Reis-Filho JS (2018) Triple-negative breast cancers—a panoply of cancer types. Nat Rev Clin Oncol 15(6):347–348PubMed
2.
Wahba HA, El-Hadaad HA (2015) Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med 12(2):106–116PubMedPubMedCentral
3.
Kalimutho M, Parsons K, Mittal D, Lopez JA, Srihari S, Khanna KK (2015) Targeted therapies for triple-negative breast cancer: combating a stubborn disease. Trends Pharmacol Sci 36(12):822–846PubMed
4.
Le Du F, Ueno NT (2015) Targeted therapies in triple-negative breast cancer: failure and future. Womens Health (Lond) 11(1):1–5
5.
Yam C, Mani SA, Moulder SL (2017) Targeting the molecular subtypes of triple negative breast cancer: understanding the diversity to progress the field. Oncologist 22(9):1086–1093PubMedPubMedCentral
6.
7.
Mayer EL, Abramson VG, Jankowitz RC, Falkson CI, Marcom PK, Traina TA, Carey LA, Rimawi MF, Specht JM, Miller K et al (2019) TBCRC 030: a randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—evaluating the homologous recombination deficiency (HRD) biomarker. J Clin Oncol 37(15_suppl):507
8.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G et al (2018) Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379(22):2108–2121PubMed
9.
Heimes AS, Schmidt M (2019) Atezolizumab for the treatment of triple-negative breast cancer. Expert Opin Investig Drugs 28(1):1–5PubMed
10.
Griguolo G, Dieci MV, Guarneri V, Conte P (2018) Olaparib for the treatment of breast cancer. Expert Rev Anticancer Ther 18(6):519–530PubMed
11.
Romero D (2019) Benefit in patients with PD-L1-positive TNBC. Nat Rev Clin Oncol 16(1):6PubMed
12.
Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart M, Rothe F, Sotiriou C (2018) Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol 29(4):895–902PubMedPubMedCentral
13.
Chiu AM, Mitra M, Boymoushakian L, Coller HA (2018) Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer. Sci Rep 8(1):11807PubMedPubMedCentral
14.
Davis SL, Eckhardt SG, Tentler JJ, Diamond JR (2014) Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Ther Adv Med Oncol 6(3):88–100PubMedPubMedCentral
15.
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W et al (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860–921PubMed
16.
Saito M, Momma T, Kono K (2018) Targeted therapy according to next generation sequencing-based panel sequencing. Fukushima J Med Sci 64(1):9–14PubMedPubMedCentral
17.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139PubMed
18.
Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 9(2):176–198PubMedPubMedCentral
19.
Mardis E (2018) Many mutations in one clinical-trial basket. Nature 554(7691):173–175PubMed
20.
Renfro LA, Sargent DJ (2017) Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol 28(1):34–43PubMed
21.
Wheler J, Lee JJ, Kurzrock R (2014) Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res 74(24):7181–7184PubMedPubMedCentral
22.
Roerink SF, Sasaki N, Lee-Six H, Young MD, Alexandrov LB, Behjati S, Mitchell TJ, Grossmann S, Lightfoot H, Egan DA et al (2018) Intra-tumour diversification in colorectal cancer at the single-cell level. Nature 556(7702):457–462PubMed
23.
24.
Dugger SA, Platt A, Goldstein DB (2018) Drug development in the era of precision medicine. Nat Rev Drug Discov 17(3):183–196PubMed
25.
Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, Majumder MM, Malani D, Murumagi A, Knowles J et al (2014) Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep 4:5193PubMedPubMedCentral
26.
Chou TC (2010) Drug combination studies and their synergy quantification using the Chou–Talalay method. Cancer Res 70(2):440–446PubMed
27.
Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621–681PubMed
28.
29.
Chou TC, Talalay P (1984) Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55PubMed
30.
Brower V (2015) NCI-MATCH pairs tumor mutations with matching drugs. Nat Biotechnol 33(8):790–791PubMed
31.
Fan J, Upadhye S, Worster A (2006) Understanding receiver operating characteristic (ROC) curves. CJEM 8(1):19–20PubMed
32.
Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1(1):78–89PubMedPubMedCentral
33.
34.
Hassan B, Akcakanat A, Sangai T, Evans KW, Adkins F, Eterovic AK, Zhao H, Chen K, Chen H, Do KA et al (2014) Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget 5(18):8544–8557PubMedPubMedCentral
35.
Guo Y, Kwiatkowski DJ (2013) Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. Mol Cancer Res 11(5):467–473PubMedPubMedCentral
36.
37.
Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB et al (2015) Dual roles of RNF2 in melanoma progression. Cancer Discov 5(12):1314–1327PubMedPubMedCentral
38.
Xu J, Pfarr N, Endris V, Mai EK, Md Hanafiah NH, Lehners N, Penzel R, Weichert W, Ho AD, Schirmacher P et al (2017) Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation. Oncogenesis 6(5):e337PubMedPubMedCentral
39.
Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K et al (2018) A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res 20(1):82PubMedPubMedCentral
40.
Chang Q, Jorgensen C, Pawson T, Hedley DW (2008) Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer 99(7):1074–1082PubMedPubMedCentral
41.
Shi H, Zhang CJ, Chen GY, Yao SQ (2012) Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes. J Am Chem Soc 134(6):3001–3014PubMed
42.
Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR et al (2013) Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 41(Database issue):D955–D961PubMed
43.
Ben-David U, Siranosian B, Ha G, Tang H, Oren Y, Hinohara K, Strathdee CA, Dempster J, Lyons NJ, Burns R et al (2018) Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560(7718):325–330PubMedPubMedCentral
44.
Kim SB, Dent R, Im SA, Espie M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ et al (2017) Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 18(10):1360–1372PubMedPubMedCentral
45.
Tamura S, Wang Y, Veeneman B, Hovelson D, Bankhead A 3rd, Broses LJ, Lorenzatti Hiles G, Liebert M, Rubin JR, Day KC et al (2018) molecular correlates of in vitro responses to dacomitinib and afatinib in bladder cancer. Bladder Cancer 4(1):77–90PubMedPubMedCentral
46.
Nagamine A, Araki T, Nagano D, Miyazaki M, Yamamoto K (2019) l-Lactate dehydrogenase B may be a predictive marker for sensitivity to anti-EGFR monoclonal antibodies in colorectal cancer cell lines. Oncol Lett 17(5):4710–4716PubMedPubMedCentral
47.
Oztop S, Isik A, Guner G, Gurdal H, Karabulut E, Yilmaz E, Akyol A (2019) Class III beta-tubulin expression in colorectal neoplasms is a potential predictive biomarker for paclitaxel response. Anticancer Res 39(2):655–662PubMed
48.
Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J et al (2015) Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genomics 8:54PubMedPubMedCentral
49.
Costa RLB, Han HS, Gradishar WJ (2018) Targeting the PI3 K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat 169(3):397–406PubMed
50.
Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D et al (2014) Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther 13(12):3175–3184PubMedPubMedCentral
51.
Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzman M, Grueso J et al (2012) PI3 K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2(11):1036–1047PubMedPubMedCentral
52.
Shimoi T, Hamada A, Yamagishi M, Hirai M, Yoshida M, Nishikawa T, Sudo K, Shimomura A, Noguchi E, Yunokawa M et al (2018) PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system. Cancer Sci 109(8):2558–2566PubMedPubMedCentral
53.
Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C et al (2017) Targeting the PI3 K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. JAMA Oncol 3(4):509–515PubMed
54.
Fouque A, Jean M, Weghe P, Legembre P (2016) Review of PI3 K/mTOR inhibitors entering clinical trials to treat triple negative breast cancers. Recent Pat Anticancer Drug Discov 11(3):283–296PubMed
55.
Stanfield Z, Coskun M, Koyuturk M (2017) Corrigendum: drug response prediction as a link prediction problem. Sci Rep 7:44961PubMedPubMedCentral
56.
Groenendijk FH, Bernards R (2014) Drug resistance to targeted therapies: deja vu all over again. Mol Oncol 8(6):1067–1083PubMedPubMedCentral
57.
Wein L, Loi S (2017) Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). Breast 34(Suppl 1):S27–S30PubMed
58.
Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J et al (2018) Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3 K inhibition in triple-negative breast cancers. Cancer Res 78(10):2732–2746PubMedPubMedCentral
59.
Wu ZH, Lin C, Liu MM, Zhang J, Tao ZH, Hu XC (2016) Src inhibition can synergize with gemcitabine and reverse resistance in triple negative breast cancer cells via the AKT/c-Jun pathway. PLoS ONE 11(12):e0169230PubMedPubMedCentral
60.
Mumin NH, Drobnitzky N, Patel A, Lourenco LM, Cahill FF, Jiang Y, Kong A, Ryan AJ (2019) Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer. BMC Cancer 19(1):102PubMedPubMedCentral
61.
Miles D, von Minckwitz G, Seidman AD (2002) Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 7(Suppl 6):13–19PubMed
62.
Lee J, Yesilkanal AE, Wynne JP, Frankenberger C, Liu J, Yan J, Elbaz M, Rabe DC, Rustandy FD, Tiwari P et al (2019) Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. Nature 568(7751):254–258PubMedPubMedCentral
Metadata
Title
Molecular determinants of drug response in TNBC cell lines
Authors
Nathan M. Merrill
Eric J. Lachacz
Nathalie M. Vandecan
Peter J. Ulintz
Liwei Bao
John P. Lloyd
Joel A. Yates
Aki Morikawa
Sofia D. Merajver
Matthew B. Soellner
Publication date
01-01-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05473-9

Other articles of this Issue 2/2020

Breast Cancer Research and Treatment 2/2020 Go to the issue

Correction

Correction to: The 3′UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1

Epidemiology

Flat epithelial atypia: are we being too aggressive?

Clinical trial

Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery

Clinical trial

Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies

Epidemiology

Body mass index and risk of breast cancer molecular subtypes in Korean women: a case–control study

Epidemiology

Association of lifestyle and clinical characteristics with receipt of radiotherapy treatment among women diagnosed with DCIS in the NIH-AARP Diet and Health Study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits